Bladt; Friedhelm

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bladt; Friedhelm.The latest application filed is for "combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor".

Company Profile

4.3.9

Bladt; Friedhelm - Heidelberg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for detecting protein modifications using specific antibodies Grant 10,996,225 - Jeahrling , et al. May 4, 2	2021-05-04
Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor Grant 10,532,052 - Bladt , et al. Ja	2020-01-14
Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor App 20190388423 - BLADT; Friedhelm ; et al.	2019-12-26
Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative Grant 10,231,972 - Bladt , et al.	2019-03-19
Combination Of A 6-oxo-1,6-dihydro-pyridazine Derivative Having Anti-cancer Activity With A Quinazoline Derivative App 20170340635 - BLADT; Friedhelm ; et al.	2017-11-30
Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor App 20170319581 - BLADT; Friedhelm ; et al.	2017-11-09
Method For Detecting Protein Modifications Using Specific Antibodies App 20170023581 - JEAHRLING; Frank ; et al.	2017-01-26
A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (RCC) App 20160331748 - BLADT; Friedhelm ; et al.	2016-11-17
Combination Of A 6-oxo-1,6-dihydro-pyridazine Derivative Having Anti-cancer Activity With Gefitinib App 20160324855 - BLADT; Friedhelm ; et al.	2016-11-10
Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor App 20150297594 - BLADT; Friedhelm ; et al.	2015-10-22
6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) App 20150283137 - Friese-Hamim; Manja ; et al.	2015-10-08
Combination Of A 6-oxo-1,6-dihydro-pyridazine Derivative Having Anti-cancer Activity With Other Anti-tumor Compounds App 20150044211 - Bladt; Friedhelm ; et al.	2015-02-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.